Biopharmaceuticals and biomedicine is a branch of medical science that applies physiological and biological principles to clinical practice. Biopharmaceuticals are extracted or manufactured from biological sources and contain variety of products such as blood factors, erythropoietin, colony stimulating factor, interferon, human growth hormone, recombinant human insulin, vaccines, monoclonal antibodies, etc. Ability to cure the disease, high effectiveness and potent action, and fewer side effects are some of the major advantages of these drugs.
The field of biotechnology has emerged as the most promising area in pharmaceutical engineering. As this technology is continuously evolving, it has started to replace traditional processes of development and manufacturing of medicines. It offers more opportunities for the medications to be manufactured at lower costs. Biopharmaceuticals and biomedicine are concentrating more on the use of botanical sources to produce essential medicines that can replace potentially hazardous chemicals. By replacing these chemicals with botanical sources, biopharmaceuticals are not only taking care of their employees' health and safety regulations but are also taking care of the environment by avoiding the use of chemicals in their products.
The aim of biopharmaceuticals and biomedicine is to utilize natural resources for the study of the living world in the disease context and prevent or treat diseases using the latest tools and technologies. Biomedicine covers all areas of life science. It combines information science, systematic and experimental methodology and biological and genetic engineering. It aims at designing and realizing medicines for a wide variety of diseases and health disorders using living organisms, cells, and other organisms. Biopharmaceuticals and biomedicine has greatly contributed towards the global health and well-being.
There are many types of biological products approved for use in the United States, such as therapeutic proteins, monoclonal antibodies, and vaccines. For instance, in February 2020, Harbour BioMed (HBM) received the U.S. Food and Drug Administration (FDA) approval for a Phase-II clinical trial of HBM9167, its humanized IgG1 monoclonal antibody targeting programmed death-ligand 1 (PD-L1), for the treatment of nasopharyngeal cancer (NPC).
